VOQUEZNA DUAL PAK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VOQUEZNA DUAL PAK (VOQUEZNA DUAL PAK).
VOQUEZNA DUAL PAK contains vonoprazan, a potassium-competitive acid blocker (P-CAB) that reversibly inhibits H+/K+-ATPase in gastric parietal cells, providing rapid and sustained acid suppression. It also contains amoxicillin, a beta-lactam antibiotic that inhibits bacterial cell wall synthesis.
| Metabolism | Vonoprazan is primarily metabolized by CYP3A4/5 and to a lesser extent by CYP2B6, CYP2C19, CYP2D6, and SULT2A1. Amoxicillin is partially metabolized by hydrolysis to penicilloic acid. |
| Excretion | Primarily renal excretion (approximately 80% as metabolites, <1% unchanged); minor biliary/fecal elimination (~15%) |
| Half-life | Terminal elimination half-life ~6-8 hours; clinically, once-daily dosing is sufficient due to pharmacodynamic effect (acid suppression) outlasting plasma levels |
| Protein binding | Approximately 95% bound to plasma proteins (primarily albumin) |
| Volume of Distribution | ~11-17 L (approx 0.15-0.25 L/kg); indicates moderate tissue distribution |
| Bioavailability | Oral: Absolute bioavailability ~70-80%; food does not significantly affect absorption |
| Onset of Action | Oral: Onset of acid suppression within 1 hour; maximum effect by 2-3 hours |
| Duration of Action | Acid suppression persists for up to 24 hours with once-daily dosing; gastric pH >4 maintained for 14-17 hours post-dose |
| Molecular Weight | 592.6 |
VOQUEZNA DUAL PAK consists of vonoprazan 20 mg (morning) and amoxicillin 1000 mg (morning and evening) for 14 days.
| Dosage form | CAPSULE, TABLET |
| Renal impairment | Contraindicated if CrCl <30 mL/min. For CrCl 30-59 mL/min, no dose adjustment needed. For CrCl <30 mL/min, not recommended. |
| Liver impairment | No dose adjustment required for mild (Child-Pugh A) or moderate (Child-Pugh B) impairment. Not studied in severe (Child-Pugh C) impairment; use with caution. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended, but monitor renal function due to age-related decline; adjust based on renal function. |
| 1st trimester | Insufficient data in pregnant women; animal studies show no evidence of teratogenicity at clinically relevant doses. Use only if potential benefit justifies risk. |
| 2nd trimester | Insufficient data; caution advised. No known fetal harm reported. |
| 3rd trimester | Insufficient data; caution advised. No known neonatal adverse effects reported. |
Clinical note
Comprehensive clinical and safety monograph for VOQUEZNA DUAL PAK (VOQUEZNA DUAL PAK).
| Placental transfer | Limited data; likely low placental transfer due to high protein binding and molecular size. |
| Breastfeeding | Excretion into human milk unknown; animal data suggest minimal transfer. Consider benefits of breastfeeding and mother's need for drug. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to vonoprazan or any componentConcomitant use with atazanavir or rilpivirine
| Precautions | Hypersensitivity reactions including anaphylaxis, Severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome), Clostridium difficile-associated diarrhea, Potential for increased risk of gastric malignancies with long-term acid suppression, Interference with laboratory tests (e.g., urine protein tests), Use in patients with renal impairment: dose adjustment for amoxicillin |
| Food/Dietary | No significant food interactions known. May be taken with or without food. Avoid alcohol during treatment as it may exacerbate gastrointestinal side effects. |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | Based on animal studies and limited human data, amoxicillin and vonoprazan are not expected to increase the risk of major birth defects. Vonoprazan has no evidence of teratogenicity in animal studies at doses up to 25 times the human exposure. Amoxicillin is considered low risk in all trimesters. However, no adequate human studies exist for the combination. |
| Fetal Monitoring | Monitor maternal renal function and for signs of hypersensitivity reactions. In pregnant women, standard prenatal care includes ultrasound for fetal growth assessment if prolonged therapy is needed. No specific fetal monitoring required for this drug combination. |
| Fertility Effects | No adverse effects on fertility have been reported for amoxicillin or vonoprazan in animal studies. Human data are insufficient to draw conclusions. |
| Clinical Pearls |
| Voquezna Dual Pak (vonoprazan and amoxicillin) is a dual therapy for Helicobacter pylori infection. Vonoprazan is a potassium-competitive acid blocker (PCAB) with rapid, potent, and sustained acid suppression, which enhances amoxicillin efficacy. Notably, no PPI metabolism issues (e.g., CYP2C19 polymorphisms) affect vonoprazan. Prescribe for 14 days; twice-daily dosing. Monitor for hypersensitivity reactions and Clostridioides difficile-associated diarrhea. Avoid in severe renal impairment (CrCl <30 mL/min) as amoxicillin accumulation risk. |
| Patient Advice | Take both tablets together twice daily, with or without food, at the same times each day for 14 days. · Complete the full course even if you feel better; stopping early may lead to treatment failure. · Swallow tablets whole; do not crush, chew, or split. · Common side effects include diarrhea, headache, and altered taste; contact your doctor if diarrhea is severe or watery. · Inform your doctor if you have kidney problems, a history of allergic reactions to penicillins, or are pregnant/breastfeeding. · Report any signs of allergic reaction (rash, itching, swelling, difficulty breathing) immediately. |